FDA approves Ferring's ZOMACTON to treat Growth Hormone Deficiency in Adults
05 February 2018 | News
GHD in adults is characterized by metabolic dysfunction, reduced physical strength and activity, altered lipid metabolism and increases in body fat
Ferring Pharmaceuticals is a research-driven biopharmaceutical company, announced the U.S. Food and Drug Administration (FDA) has approved ZOMACTON (somatropin) for Injection 5 mg and 10 mg recombinant human growth hormone (GH) indicated for replacement of GH in adults with GH deficiency.
Adult growth hormone deficiency (GHD) occurs in approximately 1-2 adults per 100,000 and can be a continuation of childhood onset growth hormone deficiency or have an onset in adulthood resulting primarily from trauma, surgery or radiation to the head.
GHD in adults is characterized by metabolic dysfunction, reduced physical strength and activity, altered lipid metabolism and increases in body fat.
ZOMACTON is also indicated for the treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone.
